Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.
Abstract
There is extensive evidence from the molecular and genomic analysis of human cancers that the PI 3-kinase (phosphoinositide 3-kinase)-Akt/PKB (protein kinase B) pathway is deregulated in malignant progression. Furthermore, the causal involvement of PI 3-kinase is supported by gene-knockout mouse models. Prototype inhibitors show evidence of anticancer activity in vitro and in vivo animal models. The recent development of isoform-selective inhibitors shows considerable promise for cancer treatment.
Collections
Subject
Animals
Mice, Knockout
Humans
Mice
Neoplasms
Disease Models, Animal
Disease Progression
Protein Isoforms
Antineoplastic Agents
Enzyme Inhibitors
Genome
Models, Chemical
Phosphatidylinositol 3-Kinases
Language
eng
License start date
2004-04
Citation
Biochemical Society transactions, 2004, 32 (Pt 2), pp. 393 - 396